Company news
PureTech Health PLC news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Holding(s) in Company
November 13, 2026
Holding(s) in Company
November 12, 2026
Holding(s) in Company
October 30, 2026
PureTech Health Wins 2026 Prix Galien USA Award
October 30, 2026
PRTC's Celea Appoints Paul Audhya, MD, MBA, as CMO
October 29, 2026
PRTC's Gallop Presents Ph1b LYT-200 Data at ESMO
October 26, 2026
PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO
October 19, 2026
PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP
October 9, 2026
PRTC's SPTX: Phase 2a Trial of GlyphAgo Initiated
October 7, 2026
Holding(s) in Company
October 7, 2026
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
September 21, 2026
PRTC's Gallop: Positive FDA Meeting & Fast Track
September 21, 2026
PRTC's SPTX: New Positive Phase 1 GlyphAllo Data
September 9, 2026
PRTC's Celea: 2 Deupirfenidone Presentations at ERS
August 25, 2026
PRTC: Celea Doses 1st Patient in Phase 3 IPF Trial
July 13, 2026
PRTC Launches Celea w/ $180M & Top Tier Syndicate
July 2, 2026
PRTC Launches Celea: $180M & Asset Transfer
July 2, 2026
PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data
June 9, 2026
Correction - Holding(s) in Company
May 15, 2026
PRTC To Showcase Deupirfenidone at ATS Conference
May 13, 2026
PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
May 1, 2026
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
April 29, 2026
PRTC Voluntarily Delists Nasdaq Depositary Shares
April 29, 2026
PRTC's Seaport Adds Neuropsychiatry Veteran to BOD
April 27, 2026
PRTC's Gallop: Positive Ph1 Topline MDS & AML Data
April 22, 2026
PRTC's Seaport Files for Proposed Nasdaq IPO
April 13, 2026
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
April 2, 2026
PRTC Publishes Phase 2b Deupirfenidone IPF Results
April 2, 2026
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
April 2, 2026
PRTC's Seaport: Positive Topline Ph1 for GlyphAgo
April 2, 2026
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
March 25, 2026
PRTC’s Seaport: GlyphAllo Paper Published
March 25, 2026
PDMR Notification RSU Vesting
March 13, 2026
Total Voting Rights
March 2, 2026
PRTC to Present at Leerink Healthcare Conference
February 25, 2026
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
February 19, 2026
PRTC's Deupirfenidone Granted FDA & EU ODD for IPF
February 19, 2026
PureTech to Present at the JP Morgan Conference
January 6, 2026
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
PureTech Appoints Robert Lyne as Chief Executive Officer
December 18, 2025
PureTech Appoints Robert Lyne as CEO
December 18, 2025
Results of AGM on June 16, 2025 – Update Statement
December 10, 2025
Holding(s) in Company
December 10, 2025
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
December 8, 2025
PRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
December 8, 2025
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
December 5, 2025
PRTC's Gallop: Positive Initial Topline AML Data
December 5, 2025
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
November 3, 2025
PRTC: New LYT-200 AML Data + Update at ASH
November 3, 2025
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
October 22, 2025
Calls
The 5 newest of 6 calls. Every call is listed under its year.
- PureTech Health (LSE:PRTC) Q2 2026 Earnings Call
Sep 22, 2026
Transcript - PureTech Health (LSE:PRTC) Q4 2025 Earnings Call
Apr 29, 2026
Transcript - PureTech Health (LSE:PRTC) Q2 2025 Earnings Call
Aug 28, 2025
Transcript - PureTech Health (LSE:PRTC) Q4 2024 Earnings Call
Apr 30, 2025
Transcript - PureTech Health (LSE:PRTC) Q2 2024 Earnings Call
Aug 28, 2024
Transcript
Decks
The 5 newest of 13 decks. Every deck is listed under its year.
- Investor Presentation (November 2026)
Investor deck · 39 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 39 slides · October 2026
- H1 2026 Earnings Presentation
Earnings · 23 slides · Sep 22, 2026
- Investor Presentation (May 2026)
Investor deck · 44 slides · May 2026
- Investor Presentation (April 2026)
Investor deck · 21 slides · Apr 1, 2026